Document is current
Any future updates will be listed below
-
Authors
Pisano, Filippo https://orcid.org/0000-0002-5499-160X
Masmudi-MartÃn, Mariam
Andriani, Maria Samuela
Cid, Elena https://orcid.org/0000-0003-4852-595X
Kazemzadeh, Mohammadrahim
Pisanello, Marco https://orcid.org/0000-0003-2179-7883
Balena, Antonio https://orcid.org/0000-0003-4314-4314
Collard, Liam
Parras, Teresa Jurado
Bianco, Marco
Baena, Patricia
Tantussi, Francesco https://orcid.org/0000-0002-0812-082X
Grande, Marco
Sileo, Leonardo
Gentile, Francesco https://orcid.org/0000-0002-1724-6301
De Angelis, Francesco https://orcid.org/0000-0001-6053-2488
De Vittorio, Massimo https://orcid.org/0000-0003-1601-6392
Menendez de la Prida, Liset https://orcid.org/0000-0002-0160-6472
Valiente, Manuel
Pisanello, Ferruccio https://orcid.org/0000-0002-1489-7758
- License Information
-
More Information
Article History
Received: 18 May 2022
Accepted: 31 October 2024
First Online: 31 December 2024
Competing interests
: L.S., M.D.V. and F. Pisanello are founders and hold private equity in Optogenix, a company that develops, produces and sells technologies to deliver light into the brain. L.S. and M.P. are employed by Optogenix. F. Pisano has been employed by Optogenix. Products of Optogenix have been used in this research. M.V. receives research funds from AstraZeneca. All other authors have no competing interests.
